title: The effects of metformin or orlistat on obese women with polycystic ovary syndrome: a prospective randomized open-label study.
abstract: OBJECTIVE
  Comparing the effects of metformin or orlistat on hormone, lipid profile and ovulation status in obese women with polycystic ovary syndrome.
  
  
  METHODS
  A total of 80 women were prospectively recruited to receive either metformin (n = 40) or orlistat (n = 40). Weight, BMI, waist, serum LH, total serum testosterone and lipid profile were assessed at baseline and after 3 months. The subjects' ovulatory status was assessed after 3 months.
  
  
  RESULTS
  There was no significant difference in ovulation between the two treatment groups (30% vs 15%). Treatment with either drug showed a significant decline in body weight, BMI (Body Mass Index), and waist circumference, but the degree of decline in both groups was the same. Patients who were treated with orlistat, showed a significant reduction in total testosterone and serum lipid. Women in metformin group showed a significant reduction in serum LH.
  
  
  CONCLUSIONS
  Both metformin and orlistat showed a similar effect on weight loss and ovulation rates.
authors.affiliation: Department of Obstetrics & Gynecology, Sabzevar University of Medical Sciences, Sabzevar, Iran. sedighe_ghandi@yahoo.com
authors.forename: Sedigheh
authors.initials: S
authors.lastname: Ghandi
authors.forename: Abbas
authors.initials: A
authors.lastname: Aflatoonian
authors.forename: Nasim
authors.initials: N
authors.lastname: Tabibnejad
authors.forename: Mohammad Hossein Sojoodi
authors.initials: MH
authors.lastname: Moghaddam
mesh_terms: D000328:Adult; D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007783:Lactones / Q000009:adverse effects / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008687:Metformin / Q000009:adverse effects / Q000627:therapeutic use*; D009765:Obesity / Q000150:complications / Q000188:drug therapy*; D000077403:Orlistat; D010060:Ovulation / Q000187:drug effects; D011085:Polycystic Ovary Syndrome / Q000150:complications / Q000503:physiopathology*; D013739:Testosterone / Q000097:blood
chemical_list: D019440:Anti-Obesity Agents; D007004:Hypoglycemic Agents; D007783:Lactones; D008055:Lipids; D013739:Testosterone; D008687:Metformin; D000077403:Orlistat